Search Results - "Cable, Rebecca"

Direct and Indirect Economic Burden of Chronic Liver Disease in the United States by Stepanova, Maria, De Avila, Leyla, Afendy, Mariam, Younossi, Issah, Pham, Huong, Cable, Rebecca, Younossi, Zobair M

“…Background & Aims Chronic liver (CLD) is a major public health concern. We assessed its effects on quality of life and work productivity, as well as its…”
Get full text

The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19 by Stepanova, Maria, Lam, Brian, Younossi, Elena, Felix, Sean, Ziayee, Mariam, Price, Jillian, Pham, Huong, de Avila, Leyla, Terra, Kathy, Austin, Patrick, Jeffers, Thomas, Escheik, Carey, Golabi, Pegah, Cable, Rebecca, Srishord, Manirath, Venkatesan, Chapy, Henry, Linda, Gerber, Lynn, Younossi, Zobair M

“…COVID-19 outcomes among hospitalized patients may have changed due to new variants, therapies and vaccine availability. We assessed outcomes of adults…”
Get full text

Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection by Younossi, Zobair M., Stepanova, Maria, Lam, Brian, Cable, Rebecca, Felix, Sean, Jeffers, Thomas, Younossi, Elena, Pham, Huong, Srishord, Manirath, Austin, Patrick, Estep, Michael, Terra, Kathy, Escheik, Carey, Avila, Leyla, Golabi, Pegah, Kolacevski, Andrej, Racila, Andrei, Henry, Linda, Gerber, Lynn

“…The impact of the coronavirus disease 2019 (COVID‐19) pandemic among patients with chronic liver disease is unknown. Given the high prevalence of nonalcoholic…”
Get full text

Statin use is not associated with liver related mortality by Younoszai, Zahra, Zheng, Li, Stepanova, Maria, Erario, Madeline, Cable, Rebecca, Younossi, Zobair M

“…AbstractBackground and Aim. Statins are commonly used medications for the treatment of dyslipidemia. Although there are reported cases of hepatotoxicity…”
Get full text

Don’t Kick the Coral by Ceponis, Peter J., MD, PhD, Dip. Sport Med, Cable, Rebecca, RN, NP, Weaver, Lindell K., MD, FACP, FCCP, FCCM, FUHM

Get full text

Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL) by Golabi, Pegah, Otgonsuren, Munkhzul, Cable, Rebecca, Felix, Sean, Koenig, Aaron, Sayiner, Mehmet, Younossi, Zobair M

“…NAFLD impacts patient reported outcomes (PROs). Our aim was to assess the impact of NAFLD on patients' HRQOL. National Health and Nutrition Examination Survey…”
Get full text

Sarcopenia Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Is Associated With Advanced Fibrosis by Harring, Michael, Golabi, Pegah, Paik, James M., Shah, Dipam, Racila, Andrei, Cable, Rebecca, Srishord, Manirath, Younossi, Zobair M.

“…Nonalcoholic fatty liver disease (NAFLD) and sarcopenia can be associated with advanced liver disease. Our aim was to assess the association between sarcopenia…”
Get full text

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis by Sayiner, Mehmet, Otgonsuren, Munkhzul, Cable, Rebecca, Younossi, Issah, Afendy, Mariam, Golabi, Pegah, Henry, Linda, Younossi, Zobair M

“…BACKGROUND:Nonalcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver disease worldwide with tremendous clinical burden. The…”
Get full text

SAT-428 - Associations of genetic risk panel with enhanced liver fibrosis scores among patients with non-alcoholic fatty liver disease by Younossi, Zobair, Estep, James M, Felix, Sean, Younossi, Elena, Rao, Nagashree Gundu, Deavila, Leyla, Pham, Huong, Cable, Rebecca, Price, Jillian, Racila, Andrei, Stepanova, Maria

Get full text

Associations of genetic risk panel with enhanced liver fibrosis scores among patients with non-alcoholic fatty liver disease by Younossi, Zobair, Estep, James M, Felix, Sean, Younossi, Elena, Rao, Nagashree Gundu, Deavila, Leyla, Pham, Huong, Cable, Rebecca, Price, Jillian, Racila, Andrei, Stepanova, Maria

Get full text

FRI418 - Estimating the clinical and economic burden of chronic hepatitis B (CHB) in the United States by Younossi, Zobair, Tampi, Radhika, Deavila, Leyla, Cable, Rebecca, Nader, Fatema, Younossi, Issah, Racila, Andrei

Get full text

Estimating the clinical and economic burden of chronic hepatitis B (CHB) in the United States by Younossi, Zobair, Tampi, Radhika, Deavila, Leyla, Cable, Rebecca, Nader, Fatema, Younossi, Issah, Racila, Andrei

Get full text

Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity by Younossi, Zobair M., Stepanova, Maria, Esteban, Rafael, Jacobson, Ira, Zeuzem, Stefan, Sulkowski, Mark, Henry, Linda, Nader, Fatema, Cable, Rebecca, Afendy, Mariam, Hunt, Sharon

“…Patient-reported outcomes (PROs) such as quality of life and work productivity are important for measuring patient's experience. We assessed PROs during and…”
Get full text

Sa1519 MODELING THE CLINICAL AND ECONOMIC EFFECTS OF ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS B (CHB) IN THE UNITED STATES (U.S.) by Younossi, Zobair M., Tampi, Radhika, de Avila, Leyla, Cable, Rebecca, Nader, Fatema, Younossi, Issah M., Racila, Andrei

Get full text

Tu1517 - Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD), Statins do not Reduce Cardiovascular or All-Cause Mortality by Golabi, Pegah, Paik, James, Bush, Haley, Cable, Rebecca, Racila, Andrei, Younossi, Zobair M.

Get full text

Sa1557 – The Value of Curing Advanced Non-Alcoholic Steatohepatitis (NASH) in the United States by Younossi, Zobair M., Tampi, Radhika, Nader, Fatema, Younossi, Issah M., Cable, Rebecca, Srishord, Manirath K., Racila, Andrei

Get full text

Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease by Younossi, Zobair M, Felix, Sean, Jeffers, Thomas, Younossi, Elena, Nader, Fatema, Pham, Huong, Afendy, Arian, Cable, Rebecca, Racila, Andrei, Younoszai, Zahra, Lam, Brian P, Golabi, Pegah, Henry, Linda, Stepanova, Maria

“…The most important surrogate for increased risk of adverse clinical outcomes among patients with nonalcoholic fatty liver disease (NAFLD) is the patient's…”
Get full text

976 Fibroscan™, FIB-4, and NAFLD Fibrosis Score as Point of Care Non-Invasive Tests for Management of Non-Alcoholic Fatty Liver Disease and Other Chronic Liver Diseases by Younossi, Zobair, Stepanova, Maria, Felix, Sean, Jeffers, Tom, Younossi, Elena, Allawi, Hossain, Cable, Rebecca, Lam, Brian, Racila, Andrei, Younossi, Issah, Henry, Linda, Ranagan, Jane, Nader, Fatema

“…INTRODUCTION: Fibroscan™ (FS) is a clinically useful tool for non-invasive assessment of fibrosis in patients with chronic liver disease (CLD). We aimed to…”
Get full text

Regular Exercise Is Associated With Low Fatigue Levels and Good Functional Outcomes After COVID-19: A Prospective Observational Study by de Avila, Leyla, Price, Jillian K., Stepanova, Maria, Lam, Brian, Weinstein, Ali A., Pham, Huong, Austin, Patrick, Keo, Wisna, Younossi, Zaid, Afendy, Mariam, Nader, Samir, Terra, Kathy, Cable, Rebecca, Younossi, Elena, Golabi, Pegah, Verma, Manisha, Nader, Fatema, Racila, Andrei, Gerber, Lynn H., Younossi, Zobair M.

“…The aim of the study is to identify the impact of postacute SARS-CoV-2 infection on patient outcomes. This is a prospective, repeated measure, observational…”
Get full text

1448-P: Enhanced Liver Fibrosis (ELF) Test Can Accurately Predict Advanced Fibrosis in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease (NAFLD) by YOUNOSSI, ZOBAIR, FELIX, SEAN, JEFFERS, THOMAS, YOUNOSSI, ELENA, NADER, FATEMA, PHAM, HUONG, AFENDY, ARIAN, CABLE, REBECCA, RACILA, ANDREI, YOUNOSZAI, ZAHRA, LAM, BRIAN P., GOLABI, PEGAH, HENRY, LINDA, CLEMENT, STEPHEN, STEPANOVA, MARIA

“…Background: The ELF test (score calculated from markers of fibrosis: hyaluronic acid, procollagen III amino-terminal peptide, and tissue inhibitor of matrix…”
Get full text